Lv11
22 积分 2026-07-29 加入
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
2小时前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
3小时前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
3小时前
已完结
Risankizumab for Ulcerative Colitis
3小时前
已完结
皖公网安备34019202002308
